Provided by Tiger Trade Technology Pte. Ltd.

Oppenheimer

115.17
+0.87000.76%
Post-market: 115.200.0300+0.03%19:30 EDT
Volume:145.77K
Turnover:16.74M
Market Cap:1.23B
PE:12.78
High:115.72
Open:113.99
Low:113.36
Close:114.30
52wk High:125.88
52wk Low:63.81
Shares:10.71M
Float Shares:6.07M
Volume Ratio:1.18
T/O Rate:2.40%
Dividend:0.77
Dividend Rate:0.67%
EPS(TTM):9.01
EPS(LYR):13.04
ROE:10.82%
ROA:2.59%
PB:1.25
PE(LYR):8.83

Loading ...

Oppenheimer Initiates ADI Global Distribution at Outperform

MT Newswires Live
·
Aug 04

Palo Alto Networks price target raised to $400 from $350 at Oppenheimer

TIPRANKS
·
Aug 04

Backblaze price target raised to $25 from $15 at Oppenheimer

TIPRANKS
·
Aug 04

Ichor Holdings price target raised to $80 from $60 at Oppenheimer

TIPRANKS
·
Aug 04

Roblox price target lowered to $50 from $82 at Oppenheimer

TIPRANKS
·
Aug 04

Ultra Clean price target raised to $150 from $115 at Oppenheimer

TIPRANKS
·
Aug 04

Oppenheimer Downgrades Integer to Market Perform From Outperform

MT Newswires Live
·
Aug 04

Inspire Medical upgraded to Outperform from Perform at Oppenheimer

TIPRANKS
·
Aug 04

Integer downgraded to Perform from Outperform at Oppenheimer

TIPRANKS
·
Aug 04

A. O. Smith Faces Near-Term Earnings Risk; Easy Comparisons, Valuation Remain Supportive, Oppenheimer Says

MT Newswires Live
·
Aug 04

Quince Therapeutics management to meet with Oppenheimer

TIPRANKS
·
Aug 04

Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says

MT Newswires Live
·
Aug 04

E.l.f. Beauty Set for Q1 Beat on Rhode Brand, Oppenheimer Says

MT Newswires Live
·
Aug 04

Ovid Therapeutics is Maintained at Outperform by Oppenheimer

Dow Jones
·
Aug 03

Ligand Pharmaceuticals Price Target Raised to $326.00/Share from $285.00 by Oppenheimer

Dow Jones
·
Aug 03

Invitation Homes is Maintained at Outperform by Oppenheimer

Dow Jones
·
Aug 03

Ares Management is Maintained at Outperform by Oppenheimer

Dow Jones
·
Aug 03

Oppenheimer Adjusts WisdomTree Price Target to $22 From $21, Maintains Outperform Rating

MT Newswires Live
·
Aug 03

Oppenheimer Adjusts Ovid Therapeutics Price Target to $9 From $7, Maintains Outperform Rating

MT Newswires Live
·
Aug 03

Oppenheimer Adjusts Invitation Homes PT to $33 From $31, Maintains Outperform Rating

MT Newswires Live
·
Aug 03